Paroxysmal kinesigenic dystonia after methylphenidate administration.
We report a patient who developed paroxysmal kinesigenic dystonia shortly after initiation of therapy with methylphenidate for presumed attention deficit-hyperactivity disorder. Attacks persisted long after methylphenidate was discontinued and responded completely to treatment with carbamazepine. Though it is possible that methylphenidate caused this syndrome in our patient, it is more likely that the stimulant triggered the onset of a genetically determined disorder.
Gay
C T
CT
Department of Pediatrics (Neurology), University of Texas Health Science Center, San Antonio 78284.
Ryan
S G
SG
D000293:Adolescent; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D002220:Carbamazepine / Q000008:administration & dosage / Q000627:therapeutic use; D004421:Dystonia / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000009:adverse effects* / Q000627:therapeutic use*
D008774:Methylphenidate; D002220:Carbamazepine